Replimune Announces Executive and Board Changes
Ticker: REPL · Form: 8-K · Filed: Mar 7, 2025 · CIK: 1737953
| Field | Detail |
|---|---|
| Company | Replimune Group, Inc. (REPL) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-change, personnel
TL;DR
Replimune's CMO is out, a new interim CMO and two new directors are in. Board shakeup.
AI Summary
Replimune Group, Inc. announced on March 5, 2025, the departure of Dr. Robert L. Kirk as Chief Medical Officer and the appointment of Dr. Philip J. Kantoff as interim Chief Medical Officer. The company also reported the election of two new directors, Dr. Kantoff and Ms. Jennifer L. Choe, to its Board of Directors.
Why It Matters
Changes in key executive and board positions can signal shifts in company strategy or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding leadership stability and strategic direction.
Key Players & Entities
- Replimune Group, Inc. (company) — Registrant
- Dr. Robert L. Kirk (person) — Departing Chief Medical Officer
- Dr. Philip J. Kantoff (person) — Appointed interim Chief Medical Officer and Director
- Ms. Jennifer L. Choe (person) — Elected Director
FAQ
Who has been appointed as the interim Chief Medical Officer for Replimune Group, Inc.?
Dr. Philip J. Kantoff has been appointed as the interim Chief Medical Officer.
When did the reported events occur?
The earliest event reported was on March 5, 2025.
Who has departed from their role as Chief Medical Officer?
Dr. Robert L. Kirk has departed from his role as Chief Medical Officer.
How many new directors were elected to the Board?
Two new directors, Dr. Philip J. Kantoff and Ms. Jennifer L. Choe, were elected to the Board.
What is the principal executive office address for Replimune Group, Inc.?
The address is 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 7, 2025 by Dr. Robert L. Kirk regarding Replimune Group, Inc. (REPL).